Oramed Pharmaceuticals (ORMP) Other Gross PP&E Adjustments (2019 - 2026)
Oramed Pharmaceuticals filings provide 12 years of Other Gross PP&E Adjustments readings, the most recent being -$1.1 million for Q4 2025.
- Quarterly Other Gross PP&E Adjustments fell 153.99% to -$1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, down 153.99% year-over-year, with the annual reading at -$1.1 million for FY2025, 153.99% down from the prior year.
- Other Gross PP&E Adjustments hit -$1.1 million in Q4 2025 for Oramed Pharmaceuticals, down from -$817000.0 in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$342000.0 in Q1 2025 and bottomed at -$1.4 million in Q1 2022.
- Average Other Gross PP&E Adjustments over 5 years is -$848600.0, with a median of -$815500.0 recorded in 2023.
- The largest annual shift saw Other Gross PP&E Adjustments tumbled 1170.71% in 2021 before it skyrocketed 47.67% in 2024.
- Oramed Pharmaceuticals' Other Gross PP&E Adjustments stood at -$534000.0 in 2021, then tumbled by 139.33% to -$1.3 million in 2022, then surged by 36.31% to -$814000.0 in 2023, then surged by 47.67% to -$426000.0 in 2024, then crashed by 153.99% to -$1.1 million in 2025.
- Per Business Quant, the three most recent readings for ORMP's Other Gross PP&E Adjustments are -$1.1 million (Q4 2025), -$817000.0 (Q3 2025), and -$882000.0 (Q2 2025).